Inhibiting endothelial factors (e.g., FASL) increases CD8+ infiltration and suppresses tumour growth, revealing an endothelial immune barrier and offering a therapeutic avenue for improving anti-tumour immunity [480]. Here, CD8A is linked to neoplasm.